Although the clinical relevance of the aforementioned cardiovascular risk factor alterations by tirzepatide is going to be assessed in the planned cardiovascular outcome research SURPASS-CVOT ( "variety":"medical-trial","attrs": "textual content":"NCT04255433","term_id":"NCT04255433" NCT04255433), a pre-specified cardiovascular meta-Evaluation indicated that tirzepatide didn't boost t... https://zionmevjy.izrablog.com/28587739/toronto-research-chemicals-an-overview